> Investors turned thumbs down on shares of NPS Pharmaceuticals after the company reported that the FDA suggested a new clinical trial for PREOS, its therapy for post-menopausal, osteoporotic women. NPS believes it can use existing data to gain FDA approval. Report
> Canada's OncoGenex is touting results from a Phase I study of OGX-011 for cancer. Report
> Bioniche Life Sciences has sold Cystistat for bladder disorder to an Irish company for $10 million. Report
> Akorn of Buffalo Grove, IL has signed a deal with Italy's Fidia Farmaceutici to develop four ANDA products. Release
> Atrium Biotechnologies is buying personal care products maker Amisol for $6 million. Report
> PPD has struck a deal to develop biomarkers for PDL BioPharma. Report
And Finally… About 40,000 AIDS patients are turning to "salvage therapies" as their bodies begin to lose their responsiveness to standard treatments. Article (WSJ sub. req.)